|
Synonyms: SGN-CD33A
Compound class:
Antibody
Comment: Vadastuximab talirine (SGN-CD33A; Seattle Genetics) is an humanized anti-CD33 antibody-drug conjugate (ADC) which delivers a toxic payload to CD33 +ve cells [1]. Talirine is a pyrrolobenzodiazepine (PBD) dimer (PubChem CID 45257190), which is a DNA crosslinking agent, causing DNA damage and ultimately apoptosis of targeted cells. Talirine is conjugated to engineered Cys residues in the antibody via a cathepsine B cleavable linker.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Vadastuximab talirine targets AML cell-expressed CD33 molecule. CD33 is expressed by approximately 90% of AML patient samples, making CD33 a major oncology target for this indication. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Acute myeloid leukemia |
Disease Ontology:
DOID:9119 OMIM: 601626 Orphanet: ORPHA519 |
FDA and EMA orphan drug for AML. | |
